Korro Bio Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
30.1%projected annual EPS growth
Analyst Coverage
10analysts covering
FY EPS (est.)
-$5.18next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Marketable Securities Quarterly157.1MTarget: Sufficient capital to fund operations into the second half of 2028
Collaboration Revenue Quarterly0.0%Target: Resumption of Novo Nordisk collaboration milestones following the 12-month pause initiated in November 2025
Preclinical SERPINA1 RNA Editing Efficiency (KRRO-111) Annually90.0Target: Maintain >90% editing of pathogenic transcripts in liver cells to support best-in-class profile
Watch Items
- Regulatory Filing for KRRO-121 in HyperammonemiaTrigger: Submission of Clinical Trial Application (CTA) or Investigational New Drug (IND) application in H2 2026Action: Verify submission timeline and transition of KRRO-121 into Phase 1 clinical development.
- Novo Nordisk Collaboration Pause ExpirationTrigger: November 2026 (marking the end of the 12-month pause initiated in November 2025)Action: Monitor for resumption of active research, development activities, and potential milestone payments.
- KRRO-111 IND-Enabling Studies and Clinical EntryTrigger: Initiation of IND-enabling studies or clinical trial applications for KRRO-111Action: Track progress of the GalNAc-conjugated AATD candidate as it advances toward clinical trials.
Research as of 19 Jun 2026